Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 16/20 | 0.38 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.32 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28242027 | 0.82 | KMO (0.40) | KMOSIRT6GRM4MEN1KMT2A | |
| SCHEMBL3034461 | 0.80 | KMO (0.56) | KMO | |
| SCHEMBL550087 | 0.80 | KMO (0.39) | KMOSIRT6GRM4MEN1KMT2A | |
| SCHEMBL31196442 | 0.78 | SIRT6 (0.50) | KMOSIRT6LMNA | |
| SCHEMBL882676 | 0.78 | KMO (0.38) | KMO | |
| SCHEMBL2774810 | 0.78 | KMO (0.38) | KMOSIRT6GRM4MEN1KMT2A | |
| SCHEMBL2774815 | 0.78 | SIRT6 (0.50) | KMOSIRT6LMNA | |
| Hydrochloric Acid SCHEMBL550088 | 0.78 | KMO (0.55) | KMO | |
| SCHEMBL22608932 | 0.74 | MALT1 (0.38) | KMOLMNA | |
| SCHEMBL31191378 | 0.74 | KMO (0.35) | KMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2386558-B1 | CGRP antagonists | BOEHRINGER INGELHEIM INT (DE) | 2014-10-01 | — | — | EP | disclosed |
| US-8450327-B2 | CGRP antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-28 | — | — | US | disclosed |
| EP-2205599-B1 | CGRP ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2012-06-06 | — | — | EP | disclosed |
| EP-2386558-A1 | CGRP antagonists | Boehringer Ingelheim International GmbH (DE) | 2011-11-16 | — | — | EP | disclosed |
| US-20110253722-A1 | METHOD AND SYSTEM FOR WATERPROOFING A MOBILE DEVICE | TOMORROW'S INNOVATIONS (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110172218-A1 | CGRP ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-14 | — | — | US | disclosed |
| EP-2205599-A1 | CGRP ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009050234-A1 | CGRP ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172218-A1 | CGRP ANTAGONISTS | CALCRL, CALCR, CALCA | KMO 2779/4885SIRT6 4547/4885GRM4 645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.